Adia Med, the medical division of Adia Nutrition Inc. (OTC Pink: ADIA), proudly announces its ongoing registration with the ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy ...

Immunocompromised patients undergoing hematopoietic stem cell transplants (HSCTs) who have a reported penicillin allergy should be evaluated as the allergy label limits access to preferred antibiotics ...

Patients with childhood and young adult cancer have an increased long-term risk for diabetes, noted as early as 10 years ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

A research team from Osaka University investigates the impact of antioxidant enzymes on specific cell types and their role in ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

The Metachromatic Leukodystrophy Initiative (MLDi) critically responds to the findings of Zhang et al. on lentivirus-modified ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nineteen analysts that are covering the firm, Ratings reports. Eight research ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...